Results Announcement for the third quarter 2015

- Issued: London, UK - Q3 sees continued progress in execution of Group strategy - Sales of £6.1 billion (+11% CER) and core EPS of 23.0p (-13% CER)

Group on track to achieve guidance for 2015 and remains confident in outlook for 2016

View full Q3 2015 results (PDF)

  • Group sales +11% CER on a reported basis and +5% CER pro-forma
  • Q3 core EPS 23.0p, -13% CER
  • Total Q3 EPS of 11.1p and 9 months EPS of 181.7p
  • 2015 earnings guidance and 2016 outlook reiterated
  • Q3 dividend of 19p declared
  • Further progress on new products and late stage pipeline
  • R&D innovation with significant potential to drive long-term performance to be profiled at Investor event on 3 November

Full details available in the quarterly results section of this website.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014.

Ansprechpartner:
Mag. Barbara Masser-Mayerl
Communications Manager,
Corporate Affairs
Tel. 01/970 75 518
barbara.b.masser-mayerl@gsk.com

GlaxoSmithKline Pharma GmbH
Euro Plaza, Gebäude I, 4. Stock
1120 Wien, Wagenseilgasse 3
at.info@gsk.com